Takafumi Sato

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Yuto Unoh, Shota Uehara, Kenji Nakahara et al. · Journal of Medicinal Chemistry · 2022 · 553 citations · Full text

<i>In Vitro</i> Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

Akinobu Ito, Takafumi Sato, Merime Ota et al. · Antimicrobial Agents and Chemotherapy · 2017 · 356 citations · Full text

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa

Akinobu Ito, Toru Nishikawa, Shuhei Matsumoto et al. · Antimicrobial Agents and Chemotherapy · 2016 · 310 citations · Full text

<i>In Vitro</i> Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

Naoki Kohira, Joshua M. West, Akinobu Ito et al. · Antimicrobial Agents and Chemotherapy · 2015 · 238 citations · Full text

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

Tsukasa Ito-Horiyama, Yoshikazu Ishii, Akinobu Ito et al. · Antimicrobial Agents and Chemotherapy · 2016 · 181 citations · Full text

Bioorganic Chemistry, Antibacterial Activity, Antimicrobial Chemotherapy +16